Trials / Unknown
UnknownNCT03116555
Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- China Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma.
Detailed description
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma. Interventions: Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day). Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities. Primary Outcome Measure: PFS. Secondary Outcome Measures: OS, ORR, DCR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2). |
| DRUG | Irinotecan | Irinotecan was used as second line treatment with AGC |
Timeline
- Start date
- 2017-04-05
- Primary completion
- 2020-03-01
- Completion
- 2020-09-01
- First posted
- 2017-04-17
- Last updated
- 2019-11-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03116555. Inclusion in this directory is not an endorsement.